Details

Autor(en) / Beteiligte

• Juhász, Vencel
• Szabó, Liliána
• Pavlik, Attila
• Tállay, András
• Balla, Dorottya
• Kiss, Orsolya
• Babity, Máté
• Sydó, Nóra
• Csulak, Emese
• Benczúr, András
• Országh, Anna
• Gregor, Zsófia
• Becker, Dávid
• Merkely, Béla
• Vágó, Hajnalka

Titel

Short and mid‐term characteristics of COVID‐19 disease course in athletes: A high‐volume, single‐center study

Ist Teil von

• Scandinavian journal of medicine & science in sports, 2023-03, Vol.33 (3), p.341-352

Ort / Verlag

Denmark: Blackwell Publishing Ltd

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Introduction At the pandemic's beginning, significant concern has risen about the prevalence of myocardial involvement after SARS‐CoV‐2 infection. We assessed the cardiovascular burden of SARS‐CoV‐2 in a large cohort of athletes and identified factors that might affect the disease course. We included 633 athletes in our study on whom we performed extensive cardiology examinations after recovering from SARS‐CoV‐2 infection. More than half of the athletes (n = 322) returned for a follow‐up examination median of 107 days after the commencement of their infection. Results Troponin T positivity was as low as 1.4% of the athletes, where the subsequently performed examinations did not show definitive, ongoing myocardial injury. Altogether, 31% of the athletes' rapid training rebuild was hindered by persistent or reoccurring symptoms. Female athletes reported a higher prevalence of return to play (RTP) symptoms than their male counterparts (34% vs. 19%, p = 0.005). The development of long COVID symptoms was independently predicted by increasing age and acute symptoms' severity in a multiple regression model (AUC 0.75, CI 0.685–0.801). Athletes presenting with either or both cough and ferritin levels higher than >150 μg/L had a 4.1x (CI 1.78–9.6, p = 0.001) higher odds ratio of developing persistent symptoms. Conclusion While SARS‐CoV‐2 rarely affects the myocardium in athletes, about one in three of them experience symptoms beyond the acute phase. Identifying those athletes with a predisposition to developing long‐standing symptoms may aid clinicians and trainers in finding the optimal return‐to‐play timing and training load rebuild pace.